101
|
Qi L, Xiao L. Convenient Synthesis and Anticancer Activity of Bis(aryl)alkanes
and Bis(indolyl)methane Alkaloid Analogs. RUSS J GEN CHEM+ 2020. [DOI: 10.1134/s1070363220100217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
102
|
Jalihal AP, Pitchiaya S, Xiao L, Bawa P, Jiang X, Bedi K, Parolia A, Cieslik M, Ljungman M, Chinnaiyan AM, Walter NG. Multivalent Proteins Rapidly and Reversibly Phase-Separate upon Osmotic Cell Volume Change. Mol Cell 2020; 79:978-990.e5. [PMID: 32857953 PMCID: PMC7502480 DOI: 10.1016/j.molcel.2020.08.004] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Revised: 06/11/2020] [Accepted: 08/05/2020] [Indexed: 12/12/2022]
Abstract
Processing bodies (PBs) and stress granules (SGs) are prominent examples of subcellular, membraneless compartments that are observed under physiological and stress conditions, respectively. We observe that the trimeric PB protein DCP1A rapidly (within ∼10 s) phase-separates in mammalian cells during hyperosmotic stress and dissolves upon isosmotic rescue (over ∼100 s) with minimal effect on cell viability even after multiple cycles of osmotic perturbation. Strikingly, this rapid intracellular hyperosmotic phase separation (HOPS) correlates with the degree of cell volume compression, distinct from SG assembly, and is exhibited broadly by homo-multimeric (valency ≥ 2) proteins across several cell types. Notably, HOPS sequesters pre-mRNA cleavage factor components from actively transcribing genomic loci, providing a mechanism for hyperosmolarity-induced global impairment of transcription termination. Our data suggest that the multimeric proteome rapidly responds to changes in hydration and molecular crowding, revealing an unexpected mode of globally programmed phase separation and sequestration.
Collapse
|
103
|
Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aich A, Aiello L, Ain A, Ajith P, Akcay S, Allen G, Allocca A, Altin PA, Amato A, Anand S, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Ansoldi S, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Aronson SM, Arun KG, Asali Y, Ascenzi S, Ashton G, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baer AM, Baird J, Baldaccini F, Ballardin G, Ballmer SW, Bals A, Balsamo A, Baltus G, Banagiri S, Bankar D, Bankar RS, Barayoga JC, Barbieri C, Barish BC, Barker D, Barkett K, Barneo P, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Benjamin MG, Bentley JD, Bergamin F, Berger BK, Bergmann G, Bernuzzi S, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bhandari AV, Bidler J, Biggs E, Bilenko IA, Billingsley G, Birney R, Birnholtz O, Biscans S, Bischi M, Biscoveanu S, Bisht A, Bissenbayeva G, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bobba F, Bode N, Boer M, Boetzel Y, Bogaert G, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Bork R, Boschi V, Bose S, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Breschi M, Briant T, Briggs JH, Brighenti F, Brillet A, Brinkmann M, Brockill P, Brooks AF, Brooks J, Brown DD, Brunett S, Bruno G, Bruntz R, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buscicchio R, Buskulic D, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callaghan JD, Callister TA, Calloni E, Camp JB, Canepa M, Cannon KC, Cao H, Cao J, Carapella G, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Castañeda J, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cesarini E, Chaibi O, Chakravarti K, Chan C, Chan M, Chandra K, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Chen HY, Chen X, Chen Y, Cheng HP, Cheong CK, Chia HY, Chiadini F, Chierici R, Chincarini A, Chiummo A, Cho G, Cho HS, Cho M, Christensen N, Chu Q, Chua S, Chung KW, Chung S, Ciani G, Ciecielag P, Cieślar M, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark JA, Clearwater P, Clesse S, Cleva F, Coccia E, Cohadon PF, Cohen D, Colleoni M, Collette CG, Collins C, Colpi M, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corezzi S, Corley KR, Cornish N, Corre D, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Croquette M, Crowder SG, Cudell JR, Cullen TJ, Cumming A, Cummings R, Cunningham L, Cuoco E, Curylo M, Canton TD, Dálya G, Dana A, Daneshgaran-Bajastani LM, D'Angelo B, Danilishin SL, D'Antonio S, Danzmann K, Darsow-Fromm C, Dasgupta A, Datrier LEH, Dattilo V, Dave I, Davier M, Davies GS, Davis D, Daw EJ, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Delfavero M, De Lillo N, Del Pozzo W, DeMarchi LM, D'Emilio V, Demos N, Dent T, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Diaz-Ortiz M, Dietrich T, Di Fiore L, Di Fronzo C, Di Giorgio C, Di Giovanni F, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Divakarla AK, Dmitriev A, Doctor Z, Donovan F, Dooley KL, Doravari S, Dorrington I, Downes TP, Drago M, Driggers JC, Du Z, Ducoin JG, Dupej P, Durante O, D'Urso D, Dwyer SE, Easter PJ, Eddolls G, Edelman B, Edo TB, Edy O, Effler A, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Ejlli A, Errico L, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Ewing BE, Fafone V, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fazio M, Feicht J, Fejer MM, Feng F, Fenyvesi E, Ferguson DL, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferreira TA, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fittipaldi R, Fitz-Axen M, Fiumara V, Flaminio R, Floden E, Flynn E, Fong H, Font JA, Forsyth PWF, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fronzè G, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Galaudage S, Ganapathy D, Ganguly A, Gaonkar SG, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Gibson DR, Gier C, Gill K, Glanzer J, Gniesmer J, Godwin P, Goetz E, Goetz R, Gohlke N, Goncharov B, González G, Gopakumar A, Gossan SE, Gosselin M, Gouaty R, Grace B, Grado A, Granata M, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green AC, Green R, Gretarsson EM, Griggs HL, Grignani G, Grimaldi A, Grimm SJ, Grote H, Grunewald S, Gruning P, Guidi GM, Guimaraes AR, Guixé G, Gulati HK, Guo Y, Gupta A, Gupta A, Gupta P, Gustafson EK, Gustafson R, Haegel L, Halim O, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hansen TJ, Hanson J, Harder T, Hardwick T, Haris K, Harms J, Harry GM, Harry IW, Hasskew RK, Haster CJ, Haughian K, Hayes FJ, Healy J, Heidmann A, Heintze MC, Heinze J, Heitmann H, Hellman F, Hello P, Hemming G, Hendry M, Heng IS, Hennes E, Hennig J, Heurs M, Hild S, Hinderer T, Hoback SY, Hochheim S, Hofgard E, Hofman D, Holgado AM, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Howell EJ, Hoy CG, Huang Y, Hübner MT, Huerta EA, Huet D, Hughey B, Hui V, Husa S, Huttner SH, Huxford R, Huynh-Dinh T, Idzkowski B, Iess A, Inchauspe H, Ingram C, Intini G, Isac JM, Isi M, Iyer BR, Jacqmin T, Jadhav SJ, Jadhav SP, James AL, Jani K, Janthalur NN, Jaranowski P, Jariwala D, Jaume R, Jenkins AC, Jiang J, Johns GR, Johnson-McDaniel NK, Jones AW, Jones DI, Jones JD, Jones P, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Kashyap R, Kasprzack M, Kastaun W, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kéfélian F, Keitel D, Keivani A, Kennedy R, Key JS, Khadka S, Khalili FY, Khan I, Khan S, Khan ZA, Khazanov EA, Khetan N, Khursheed M, Kijbunchoo N, Kim C, Kim GJ, Kim JC, Kim K, Kim W, Kim WS, Kim YM, Kimball C, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Knyazev E, Koch P, Koehlenbeck SM, Koekoek G, Koley S, Kondrashov V, Kontos A, Koper N, Korobko M, Korth WZ, Kovalam M, Kozak DB, Kringel V, Krishnendu NV, Królak A, Krupinski N, Kuehn G, Kumar A, Kumar P, Kumar R, Kumar R, Kumar S, Kuo L, Kutynia A, Lackey BD, Laghi D, Lalande E, Lam TL, Lamberts A, Landry M, Lane BB, Lang RN, Lange J, Lantz B, Lanza RK, La Rosa I, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche YK, Lee CH, Lee HM, Lee HW, Lee J, Lee K, Lehmann J, Leroy N, Letendre N, Levin Y, Li AKY, Li J, Li K, Li TGF, Li X, Linde F, Linker SD, Linley JN, Littenberg TB, Liu J, Liu X, Llorens-Monteagudo M, Lo RKL, Lockwood A, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Ma Y, Macas R, Macfoy S, MacInnis M, Macleod DM, MacMillan IAO, Macquet A, Magaña Hernandez I, Magaña-Sandoval F, Magee RM, Majorana E, Maksimovic I, Malik A, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Mapelli M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin IW, Martin RM, Martinez V, Martynov DV, Masalehdan H, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Mavalvala N, Maynard E, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIsaac C, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Mehta AK, Mejuto Villa E, Melatos A, Mendell G, Mercer RA, Mereni L, Merfeld K, Merilh EL, Merritt JD, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Meylahn F, Mhaske A, Miani A, Miao H, Michaloliakos I, Michel C, Middleton H, Milano L, Miller AL, Millhouse M, Mills JC, Milotti E, Milovich-Goff MC, Minazzoli O, Minenkov Y, Mishkin A, Mishra C, Mistry T, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Mo G, Mogushi K, Mohapatra SRP, Mohite SR, Molina-Ruiz M, Mondin M, Montani M, Moore CJ, Moraru D, Morawski F, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mozzon S, Muciaccia F, Mukherjee A, Mukherjee D, Mukherjee S, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Murray PG, Nagar A, Nardecchia I, Naticchioni L, Nayak RK, Neil BF, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Ng KY, Ng S, Nguyen C, Nguyen P, Nichols D, Nichols SA, Nissanke S, Nitz A, Nocera F, Noh M, North C, Nothard D, Nuttall LK, Oberling J, O'Brien BD, Oganesyan G, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Olivetto C, Oppermann P, Oram RJ, O'Reilly B, Ormiston RG, Ortega LF, O'Shaughnessy R, Ossokine S, Osthelder C, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page MA, Pagliaroli G, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pan H, Panda PK, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Payne E, Pearlstone BL, Pechsiri TC, Pedersen AJ, Pedraza M, Pele A, Penn S, Perego A, Perez CJ, Périgois C, Perreca A, Perriès S, Petermann J, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piendibene M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Piotrzkowski K, Pirello M, Pitkin M, Plastino W, Poggiani R, Pong DYT, Ponrathnam S, Popolizio P, Porter EK, Powell J, Prajapati AK, Prasai K, Prasanna R, Pratten G, Prestegard T, Principe M, Prodi GA, Prokhorov L, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quinonez PJ, Raab FJ, Raaijmakers G, Radkins H, Radulesco N, Raffai P, Rafferty H, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rao K, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Rettegno P, Ricci F, Richardson CJ, Richardson JW, Ricker PM, Riemenschneider G, Riles K, Rizzo M, Robertson NA, Robinet F, Rocchi A, Rodriguez-Soto RD, Rolland L, Rollins JG, Roma VJ, Romanelli M, Romano R, Romel CL, Romero-Shaw IM, Romie JH, Rose CA, Rose D, Rose K, Rosińska D, Rosofsky SG, Ross MP, Rowan S, Rowlinson SJ, Roy PK, Roy S, Roy S, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salafia OS, Salconi L, Saleem M, Salemi F, Samajdar A, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sanders JR, Santiago KA, Santos E, Sarin N, Sassolas B, Sathyaprakash BS, Sauter O, Savage RL, Savant V, Sawant D, Sayah S, Schaetzl D, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schulte BW, Schutz BF, Schwarm O, Schwartz E, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer T, Sharifi S, Shahriar MS, Sharma A, Sharma P, Shawhan P, Shen H, Shikauchi M, Shink R, Shoemaker DH, Shoemaker DM, Shukla K, ShyamSundar S, Siellez K, Sieniawska M, Sigg D, Singer LP, Singh D, Singh N, Singha A, Singhal A, Sintes AM, Sipala V, Skliris V, Slagmolen BJJ, Slaven-Blair TJ, Smetana J, Smith JR, Smith RJE, Somala S, Son EJ, Soni S, Sorazu B, Sordini V, Sorrentino F, Souradeep T, Sowell E, Spencer AP, Spera M, Srivastava AK, Srivastava V, Staats K, Stachie C, Standke M, Steer DA, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson S, Stocks D, Stops DJ, Stover M, Strain KA, Stratta G, Strunk A, Sturani R, Stuver AL, Sudhagar S, Sudhir V, Summerscales TZ, Sun L, Sunil S, Sur A, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Tanasijczuk AJ, Tanner DB, Tao D, Tápai M, Tapia A, Tapia San Martin EN, Tasson JD, Taylor R, Tenorio R, Terkowski L, Thirugnanasambandam MP, Thomas M, Thomas P, Thompson JE, Thondapu SR, Thorne KA, Thrane E, Tinsman CL, Saravanan TR, Tiwari S, Tiwari S, Tiwari V, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Tosta E Melo I, Töyrä D, Travasso F, Traylor G, Tringali MC, Tripathee A, Trovato A, Trudeau RJ, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tsutsui T, Turconi M, Ubhi AS, Udall R, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Utina AC, Vahlbruch H, Vajente G, Valdes G, Valentini M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, Van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Veske D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vivanco FH, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace GS, Wallace L, Walsh S, Wang JZ, Wang S, Wang WH, Ward RL, Warden ZA, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Weßels P, Westhouse JW, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken DM, Williams D, Willis JL, Willke B, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wong ICF, Wright JL, Wu DS, Wysocki DM, Xiao L, Yamamoto H, Yang L, Yang Y, Yang Z, Yap MJ, Yazback M, Yeeles DW, Yu H, Yu H, Yuen SHR, Zadrożny AK, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang T, Zhao C, Zhao G, Zhou M, Zhou Z, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. GW190521: A Binary Black Hole Merger with a Total Mass of 150 M_{⊙}. PHYSICAL REVIEW LETTERS 2020; 125:101102. [PMID: 32955328 DOI: 10.1103/physrevlett.125.101102] [Citation(s) in RCA: 73] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 06/19/2020] [Accepted: 07/09/2020] [Indexed: 06/08/2023]
Abstract
On May 21, 2019 at 03:02:29 UTC Advanced LIGO and Advanced Virgo observed a short duration gravitational-wave signal, GW190521, with a three-detector network signal-to-noise ratio of 14.7, and an estimated false-alarm rate of 1 in 4900 yr using a search sensitive to generic transients. If GW190521 is from a quasicircular binary inspiral, then the detected signal is consistent with the merger of two black holes with masses of 85_{-14}^{+21} M_{⊙} and 66_{-18}^{+17} M_{⊙} (90% credible intervals). We infer that the primary black hole mass lies within the gap produced by (pulsational) pair-instability supernova processes, with only a 0.32% probability of being below 65 M_{⊙}. We calculate the mass of the remnant to be 142_{-16}^{+28} M_{⊙}, which can be considered an intermediate mass black hole (IMBH). The luminosity distance of the source is 5.3_{-2.6}^{+2.4} Gpc, corresponding to a redshift of 0.82_{-0.34}^{+0.28}. The inferred rate of mergers similar to GW190521 is 0.13_{-0.11}^{+0.30} Gpc^{-3} yr^{-1}.
Collapse
|
104
|
Xiao L, Zhang Y, Lin Q. 442P Camrelizumab combined with apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: One-arm exploratory clinical trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.553] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
105
|
Xiao L, Li T. 1467P The development and verification of nomogram to predict the survival prognosis of patients with esophageal squamous cell carcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
106
|
Xie Q, Wang J, You JL, Zhu SD, Zhou R, Tian ZJ, Wu H, Lin Y, Chen W, Xiao L, Li JJ, Dong J, Wu HL, Zhang W, Li J, Mu F, Xu X, Yin Y, Chen WJ, Wang J. [The role of large-scale testing platform in the prevention and control of the COVID-19 pandemic: an empirical study based on a novel numerical model]. ZHONGHUA YI XUE ZA ZHI 2020; 100:2532-2536. [PMID: 32829601 DOI: 10.3760/cma.j.cn112137-20200320-00860] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: China adopted an unprecedented province-scale quarantine since January 23rd 2020, after the novel coronavirus (COVID-19) broke out in Wuhan in December 2019. Responding to the challenge of limited testing capacity, large-scale (>20 000 tests per day) standardized and fully-automated laboratory (Huo-Yan) was built as an ad-hoc measure. There is so far no empirical data or mathematical model to reveal the impact of the testing capacity improvement since quarantine. Methods: Based on the suspected case data released by the Health Commission of Hubei Province and the daily testing data of Huo-Yan Laboratory, the impact of detection capabilities on the realization of "clearing" and "clearing the day" of supected cases was simulated by establishing a novel non-linear and competitive compartments differential model. Results: Without the establishment of Huo-Yan, the suspected cases would increase by 47% to 33 700, the corresponding cost of quarantine would be doubled, the turning point of the increment of suspected cases and the achievement of "daily settlement" (all newly discovered suspected cases are diagnosed according to the nucleic acid testing result) would be delayed for a whole week and 11 days. If the Huo-Yan Laboratory could ran at its full capacity, the number of suspected cases could start to decrease at least a week earlier, the peak of suspected cases would be reduced by at least 44%, and the quarantine cost could be reduced by more than 72%. Ideally, if a daily testing capacity of 10 500 tests was achieved immediately after the Hubei lockdown, "daily settlement" for all suspected cases could be achieved. Conclusions: Large-scale, standardized clinical testing platform, with nucleic acid testing, high-throughput sequencing, and immunoprotein assessment capabilities, need to be implemented simultaneously in order to maximize the effect of quarantine and minimize the duration and cost of the quarantine. Such infrastructure, for both common times and emergencies, is of great significance for the early prevention and control of infectious diseases.
Collapse
|
107
|
Fu S, Li Z, Xiao L, Hu W, Zhang L, Xie B, Zhou Q, He J, Qiu Y, Wen M, Peng Y, Gao J, Tan R, Deng Y, Weng L, Sun LQ. Glutamine Synthetase Promotes Radiation Resistance via Facilitating Nucleotide Metabolism and Subsequent DNA Damage Repair. Cell Rep 2020; 28:1136-1143.e4. [PMID: 31365859 DOI: 10.1016/j.celrep.2019.07.002] [Citation(s) in RCA: 81] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2019] [Revised: 03/12/2019] [Accepted: 06/27/2019] [Indexed: 01/10/2023] Open
Abstract
Radiation resistance is a critical problem in radiotherapy for cancer. Radiation kills tumor cells mainly through causing DNA damage. Thus, efficiency of DNA damage repair is one of the most important factors that limits radiotherapy efficacy. Glutamine physiologically functions to generate protein and nucleotides. Here, we study the impact of glutamine metabolism on cancer therapeutic responses, in particular under irradiation-induced stress. We show that radiation-resistant cells possessed low glycolysis, mitochondrial respiration, and TCA cycle but high glutamine anabolism. Transcriptome analyses revealed that glutamine synthetase (GS), an enzyme catalyzing glutamate and ammonia to glutamine, was responsible for the metabolic alteration. ChIP and luciferase reporter assays revealed that GS could be transcriptionally regulated by STAT5. Knockdown of GS delayed DNA repair, weakened nucleotide metabolism, and enhanced radiosensitivity both in vitro and in vivo. Our data show that GS links glutamine metabolism to radiotherapy response through fueling nucleotide synthesis and accelerating DNA repair.
Collapse
|
108
|
Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM. Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Androgen receptor (AR) signaling is critical for prostate development and homeostasis as well as for the initiation and progression of prostate cancer (PCa). Indeed, the clinical development of second-generation AR antagonists, including enzalutamide, has confirmed that AR remains a key oncogene in castration-resistant prostate cancer (CRPC). Furthermore, response to enzalutamide is temporary and incremental, and PCa cells that develop resistance to AR-targeted therapy usually maintain AR expression. Therefore, with the hypothesis that AR protein is still active even during castration- and enzalutamide-resistant states, we employed the proteolysis targeting chimera (PROTAC) strategy to build compounds that targeted the AR through proteasomal degradation. We developed an optimized functional molecule, ARD-61, that targets enzalutamide-resistant and AR splice variant (including AR-V7, which lacks the ligand binding domain) overexpressing cells in vitro and in vivo.
Methods/Results: To characterize ARD-61, we performed western blotting, qRT-PCR, growth assays, xenograft studies, as well as proteomic and RNA-sequencing analyses. Additionally, to investigate the sensitivity of AR splice variants to ARD-61, we created CRISPR-Cas9 mediated stable AR-V7 overexpression in LNCaP cells. ARD-61 functions to rapidly and specifically degrade AR protein, and thus decreases downstream AR signaling in a wide variety (e.g. enzalutamide sensitive, AR-mutated, enzalutamide resistant) of AR-positive cell lines and tumor xenografts. Enzalutamide-sensitive and -resistant cell lines were similarly sensitive to ARD-61 in vivo and in vitro. CRISPR-induced endogenous overexpression of AR-V7 had no effect on the sensitivity of cells to ARD-61 or enzalutamide.
Conclusions: Our data reveal the necessity of full-length AR in all Pca stages. Despite continued AR-antagonization, enzalutamide-resistant cell lines require full-length AR for sustained survival. Further, AR-variant overexpression, previously shown to promote resistance to AR-targeted therapies, still required AR protein with an intact ligand-binding domain to maintain growth in our models. Our data illustrate the importance of continued targeting of AR in advanced Pca, as well as demonstrate the efficacy of ARD-61. Ultimately, through its clinical translation, we anticipate the development of ARD-61 to be a therapeutic advance for patients with the metastatic CRPC.
Citation Format: Steven Kregel, Chao Wang, Xin Han, Lanbo Xiao, Ester Fernandez-Salas, Pushpinder Bawa, Brooke L. McCollum, Kari Wilder-Romans, Ingrid J. Apel, Xuhong Cao, Corey Speers, Shaomeng Wang, Arul M. Chinnaiyan. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5679.
Collapse
|
109
|
Cheng C, Xiao L, Tien J, Wang C, Cheng J, Shiau E, Wang X, Chinnaiyan AM. Abstract 1278: Elucidating the mechanistic role of ERG in prostate cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-1278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The transcription factor ERG is important for the development of angiogenesis, blood vessel integrity, and maintenance of hematopoietic stem cells. However, aberrant overexpression of ERG has been shown to be associated with various cancers. For example, ERG is recurrently involved in a translocation with TMPRSS2, which shifts it under AR regulation, and is thus subjected to overexpression in about 50% of prostate cancers in Caucasian males. While the clinical prognostic value of the TMPRSS2:ERG fusion is still debated, mechanistic studies of ERG-positive prostate cancers have demonstrated that ERG promotes cell invasion and metastasis. However, the molecular and cellular mechanisms of oncogenic ERG function in prostate cancer remain largely unclear.
Methods/Results: To more comprehensively study the molecular and phenotypic roles of the TMPRSS2:ERG fusion product in prostate cancer, we developed an inducible ERG overexpression model in multiple cell lines as well as a CRISPR-Cas9-mediated TMPRSS2:ERG fusion translocation model. Using these models, we first performed RNA-seq and observed that ERG overexpression induced a global transcriptional program that increased the expression of genes related to epithelial-mesenchymal transition and decreased the expression of genes related to cell-cycle promotion. Further, using Boyden Chamber Assays as well as IncuCyte, we showed that overexpression of ERG promoted cell invasion but suppressed cell proliferation. We then used flow cytometric analysis to show that cells overexpressing ERG undergo a prolonged S phase. Interestingly, ERG antagonization through peptidomimetic inhibition partially rescued the proliferation rates of these ERG-overexpressing cells. Finally, using genome-wide CRISPR/Cas9 screening and NGS of the integrated sgRNA expression cassettes in the inducible ERG model, we identified panels of genes mediating ERG functions.
Discussion: Unlike oncogenic kinases such as BCR-ABL in Chronic Myeloid Leukemia, transcription factors such as ERG have been more challenging to directly target in cancer. Thus, elucidation of the mechanisms of ERG-mediated transcriptional reprogramming, ERG binding partners, as well as the regulation of ERG, may result in the development of new strategies to target ERG by selectively antagonizing ERG oncogenic functions. Using our models, we are able to gain a better understanding of the role of ERG in cancer development and progression and thus provide insight for the development of new strategies for the prevention, detection, and treatment of prostate cancer.
Citation Format: Caleb Cheng, Lanbo Xiao, Jean Tien, Cynthia Wang, Jesse Cheng, Eileen Shiau, Xiaoju Wang, Arul M. Chinnaiyan. Elucidating the mechanistic role of ERG in prostate cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1278.
Collapse
|
110
|
Li P, Wang Z, Lu Y, Li N, Xiao L, Su J, Duan H, Liu X, Wu W. Assessment of knee extensor and flexor function using isokinetic test in COPD: impact on exercise capacity. Int J Tuberc Lung Dis 2020; 24:776-781. [PMID: 32912381 DOI: 10.5588/ijtld.19.0588] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE: To quantify the relationship between strength and endurance of knee extensor and flexor and exercise capacity in patients with chronic obstructive pulmonary disease (COPD).METHODS: A total of 108 patients with stable COPD (age: 65 years, IQR25-75: 59-72) were enrolled in this cross-sectional study. Knee extensor and flexor function was evaluated using the isokinetic test, and the parameters attained were considered as independent variables. Exercise capacity was evaluated using 6-minute walking test (6MWT) and 30-second sit-to-stand test (30s SST), and the results were considered as dependent variables. The association between lower-limb muscle function and exercise capacity was assessed using multiple regression analysis.RESULTS: The patients mostly had moderate-to-severe airflow obstruction with a post-bronchodilator forced expiratory volume in 1 second (FEV1) of 57.87 ± 17.71% predicted. In multiple regression analysis, flexor total work (TW), extensor endurance ratio (ER), age and FEV1%pred were significantly associated with 6MWT (adjusted R² = 0.455, P < 0.001). Flexor TW and age were significantly associated with 30s SST (adjusted R² = 0.355, P < 0.001).CONCLUSION: Knee endurance has a significant relationship with exercise capacity, and knee flexor endurance seems to be an important factor contributing to exercise capacity in COPD patients.
Collapse
|
111
|
Huang C, Xiao L, Luo HL, Zhu ZM. Preoperative neutrophil-to-lymphocyte ratio combined with serum CEA, CA19-9, CA125 and CA72-4 levels in the clinical pathological staging of gastric cancer-based on propensity score matching. J BIOL REG HOMEOS AG 2020; 34:1111-1116. [PMID: 32657111 DOI: 10.23812/19-458-l-46] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
112
|
Xie L, Xiao L, Kuang D, Jiang Y, Yang Y. [Influencing factors on smoking cessation among outpatients from the National Central Subsidy Smoking Cessation Clinic Project, in 2015-2018]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2020; 41:890-895. [PMID: 32564555 DOI: 10.3760/cma.j.cn112338-20191104-00780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the effect of smoking cessation project run by the Central Subsidy Smoking Cessation Clinic and to explore the related influencing factors on smoking cessation, in order to improve related services and provide better guidance to these smoking cessation clinics. Methods: Practitioners who had been trained to run smoking cessation projects were recruited to conduct face-to-face interview with the smokers. Questionnaires were completed to provide information on related psychological, social and behavioral issues. In these clinics, medications were provided to the patients by the health care takers in the clinic. One month after the first visit, smoking cessation rate (self-reported, 7-day point prevalence abstinence rate at 30-day follow-up) was counted. Results: The overall smoking cessation rate (self-reported, 7-day point prevalence abstinence rate at 30-day follow-up) appeared as 34.1%. Results from the multivariate logistic regression showed that patients over the age of 60 were the ones most likely to quit smoking. Smokers who showed higher possibility of quitting would include those: not on the daily base, intend to quit within 30 days, with other diseases, or taking varenicline and bupropion. Factors as unemployment, longer history of smoking, bigger quantity of cigarettes consumption per day, dependence on nicotine and urgency on taking up the first cigarette in the early morning etc., were related to the less likelihood of giving up smoking. However, histories of cessation did not seem to affect the possibility of quitting. Conclusions: Data from self-reported 7-day point prevalence abstinence at 30-day follow-up study showed that the smoking cessation intervention programs run by the central subsidy smoking cessation clinic project had been effectively implemented. Advocacy on quit smoking at early stage seemed to have better outcomes, thus should be called for. Since medications as varenicline tartrate and bupropion hydrochloride can increase the possibility of stop smoking, we would suggest that all the hospitals which are with smoking cessation clinics be equipped with these medicines. Professional assistance provided by practitioners is of key importance to help overcome the withdrawal symptoms during the periods of cessation, on these smokers.
Collapse
|
113
|
Chen D, Li H, Zhao Y, Qiu Y, Xiao L, He H, Zheng D, Li X, Huang L, Yu X, Xu N, Hu X, Chen Y, Chen F. Characterization of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in Fuzhou, China. J Appl Microbiol 2020; 129:1220-1226. [PMID: 32396222 PMCID: PMC7687251 DOI: 10.1111/jam.14700] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 04/07/2020] [Accepted: 05/05/2020] [Indexed: 02/06/2023]
Abstract
Aims The emergence of carbapenem‐resistant Klebsiella pneumoniae (CRKP) strains has led to increased mortality and morbidity rates. Tigecycline, a new class of broad‐spectrum glycyl‐tetracycline antibiotics, has been used to target multi‐ and pan‐drug‐resistant bacterial infections. This study aimed to assess the molecular characteristics of CRKP in a tertiary hospital, and its susceptibility to tigecycline, to create a reference for hospital infection control and clinical drug use. Methods and Results We retrieved patient clinical information and CRKP characterization from medical records and detected the MIC of tigecycline using the micro‐broth dilution method. Multi‐locus sequence typing was performed, and antibiotic resistance genes associated with CRKP were detected by qPCR. A total of 166 CRKP strains were detected in the sputum, urine and blood among intensive care unit patients (average age, 69·6 years). The most infrequently observed resistance genes were amikacin resistance genes, followed by tobramycin resistance genes. KPC‐2, CTX‐M9 and CTX‐M1 were the most frequently detected resistance genes. Conclusions No strain was resistant to tigecycline (MIC ≥ 8 µg ml−1). Twenty‐four sequence types were identified, with ST11 being the most common type. Significance and Impact of the Study Clinicians and infection control experts should be aware of CRKP prevalence to facilitate clinical treatment and improve nosocomial infection control.
Collapse
|
114
|
Brown J, Shah P, Vo J, Xiao L, Niknafs Y, Cao X, Chinnaiyan A. Noninvasive identification of lineage-specific circular RNA for ER-positive breast cancer. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.3543] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3543 Background: Non-invasive testing in plasma using RNA biomarkers has been limited by exoribonuclease-mediated degradation of RNA. Circular RNA (circRNA) are covalently closed RNA structures that resist this degradation due to their circular structure. Therefore circRNA are more stable than their linear counterparts. CircRNA are formed by alternative backsplicing of the 3’ end of a downstream exon to the 5’ end of an upstream exon. Here, we propose a novel method for non-invasive identification of circRNA and demonstrate circularized forms of several lineage and cancer specific targets for estrogen receptor-positive breast cancer. Methods: Capture RNA sequencing on cancer tissue was previously performed to determine the relative expression of potential circRNA isoforms in breast cancer patients. These isoforms as well as those predicted by intron length were screened using a quantitative PCR-based assay on ER-positive breast cancer cells. RNA extracted from breast cancer cells are exposed to ribonuclease R to demonstrate stability of circRNA. CircRNA derived from targets with known universal expression are used as positive controls as well as for analysis on plasma. Results: We identify the circRNA isoforms with highest expression for five genes, including ESR1, that are differentially expressed in ER-positive breast cancer compared to other cancers and normal breast tissue. We determine that the circRNA corresponding to all five targets is specifically expressed in breast cancer cell lines with at least 1000-fold higher expression than in non-ER positive breast cancer cell lines. We demonstrate that the highest expressing circRNA isoforms are resistant to degradation by ribonuclease R, whereas corresponding linear mRNA is susceptible. We also demonstrate the presence and stability of positive control circRNA in plasma from patients without cancer. Conclusions: CircRNA are promising biomarkers for early non-invasive detection of cancer due to their stability in plasma. This assay reliably detects ER-positive breast cancer specific circRNA, and exoribonuclease resistance has been validated. Application of this diagnostic assay to plasma from breast cancer patients is underway.
Collapse
|
115
|
Yu M, Xiao L, Chen Y, Wang H, Gao Y, Wang A. Identification of a potential target for treatment of squamous cell carcinoma of the tongue: follistatin. Br J Oral Maxillofac Surg 2020; 58:437-442. [PMID: 32115303 DOI: 10.1016/j.bjoms.2020.01.028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 01/29/2020] [Indexed: 11/24/2022]
Abstract
Squamous cell carcinoma (SCC) of the tongue is the most common oral cancer and is prone to develop regional lymph nodes and distant metastases. Reliable and stable therapeutic targets can improve the curative effect and reduce toxic side effects caused by traditional treatments such as surgery, radiotherapy, and chemotherapy. We have analysed three sets of series of functional gene expression of SCC of the tongue from gene expression omnibus (GEO) datasets, and 154 common differentially expressed genes (DEG) between SCC of the tongue and the corresponding normal tissues were screened. Further bioinformatics research that was based on the data from the Cancer genome atlas, Gene ontology, and the Kyoto encyclopaedia of genes and genomes indicated that the increased expression of follistatin might be correlated with a poor prognosis in these patients. By assay of colony formation, reverse transcription polymerase chain reaction (RT-PCR), western blotting, immunohistochemical staining, and lentivirus transfection, we confirmed that downregulation of follistatin inhibited the proliferation of SCC cells in the tongue.
Collapse
|
116
|
Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia 2020; 22:111-119. [PMID: 31931431 PMCID: PMC6957805 DOI: 10.1016/j.neo.2019.12.003] [Citation(s) in RCA: 85] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 12/13/2019] [Indexed: 12/25/2022]
Abstract
Androgen receptor (AR) antagonists, such as enzalutamide, have had a major impact on the treatment of metastatic castration-resistant prostate cancer (CRPC). However, even with the advent of AR antagonist therapies, patients continue to develop resistance, and new strategies to combat continued AR signalling are needed. Here, we develop AR degraders using PROteolysis TArgeting Chimeric (PROTAC) technology in order to determine whether depletion of AR protein can overcome mechanisms of resistance commonly associated with current AR-targeting therapies. ARD-61 is the most potent of the AR degraders and effectively induces on-target AR degradation with a mechanism consistent with the PROTAC design. Compared to clinically-approved AR antagonists, administration of ARD-61 in vitro and in vivo results in more potent anti-proliferative, pro-apoptotic effects and attenuation of downstream AR target gene expression in prostate cancer cells. Importantly, we demonstrate that ARD-61 functions in enzalutamide-resistant model systems, characterized by diverse proposed mechanisms of resistance that include AR amplification/overexpression, AR mutation, and expression of AR splice variants, such as AR-V7. While AR degraders are unable to bind and degrade AR-V7, they continue to inhibit tumor cell growth in models overexpressing AR-V7. To further explore this, we developed several isogenic prostate cell line models in which AR-V7 is highly expressed, which also failed to influence the cell inhibitory effects of AR degraders, suggesting that AR-V7 is not a functional resistance mechanism for AR antagonism. These data provide compelling evidence that full-length AR remains a prominent oncogenic driver of prostate cancers which have developed resistance to AR antagonists and highlight the clinical potential of AR degraders for treatment of CRPC.
Collapse
|
117
|
Abbott BP, Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Akutsu T, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Ando M, Angelova SV, Antier S, Appert S, Arai K, Arai K, Arai Y, Araki S, Araya A, Araya MC, Areeda JS, Arène M, Aritomi N, Arnaud N, Arun KG, Ascenzi S, Ashton G, Aso Y, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae SW, Bae YB, Baiotti L, Bajpai R, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton MA, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bidler J, Bilenko IA, Bilgili SA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bode N, Boer M, Boetzel Y, Bogaert G, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Briggs JH, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DA, Brown DD, Brunett S, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Bustillo JC, Callister TA, Calloni E, Camp JB, Campbell WA, Canepa M, Cannon K, Cannon KC, Cao H, Cao J, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Diaz JC, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chakravarti K, Chamberlin SJ, Chan M, Chan ML, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Cheeseboro BD, Chen CS, Chen HY, Chen KH, Chen X, Chen Y, Chen YR, Cheng HP, Cheong CK, Chia HY, Chincarini A, Chiummo A, Cho G, Cho HS, Cho M, Christensen N, Chu HY, Chu Q, Chu YK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colgan R, Colleoni M, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Croquette M, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D’Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Datrier LEH, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Pozzo WD, DeMarchi LM, Demos N, Dent T, De Pietri R, Derby J, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Dietrich T, Fiore LD, Giovanni MD, Girolamo TD, Lieto AD, Ding B, Pace SD, Palma ID, Renzo FD, Dmitriev A, Doctor Z, Doi K, Donovan F, Dooley KL, Doravari S, Dorrington I, Downes TP, Drago M, Driggers JC, Du Z, Ducoin JG, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eguchi S, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Enomoto Y, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fazio M, Fee C, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferreira TA, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fitz-Axen M, Flaminio R, Fletcher M, Flynn E, Fong H, Font JA, Forsyth PWF, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fujii Y, Fukunaga M, Fukushima M, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Ge GG, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Giazotto A, Gill K, Giordano G, Glover L, Godwin P, Goetz E, Goetz R, Goncharov B, González G, Castro JMG, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green AC, Green R, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Gulati HK, Guo Y, Gupta A, Gupta MK, Gustafson EK, Gustafson R, Haegel L, Hagiwara A, Haino S, Halim O, Hall BR, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Haris K, Harms J, Harry GM, Harry IW, Hasegawa K, Haster CJ, Haughian K, Hayakawa H, Hayama K, Hayes FJ, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Heurs M, Hild S, Himemoto Y, Hinderer T, Hiranuma Y, Hirata N, Hirose E, Hoak D, Hochheim S, Hofman D, Holgado AM, Holland NA, Holt K, Holz DE, Hong Z, Hopkins P, Horst C, Hough J, Howell EJ, Hoy CG, Hreibi A, Hsieh BH, Huang GZ, Huang PW, Huang YJ, Huerta EA, Huet D, Hughey B, Hulko M, Husa S, Huttner SH, Huynh-Dinh T, Idzkowski B, Iess A, Ikenoue B, Imam S, Inayoshi K, Ingram C, Inoue Y, Inta R, Intini G, Ioka K, Irwin B, Isa HN, Isac JM, Isi M, Itoh Y, Iyer BR, Izumi K, Jacqmin T, Jadhav SJ, Jani K, Janthalur NN, Jaranowski P, Jenkins AC, Jiang J, Johnson DS, Jones AW, Jones DI, Jones R, Jonker RJG, Ju L, Jung K, Jung P, Junker J, Kajita T, Kalaghatgi CV, Kalogera V, Kamai B, Kamiizumi M, Kanda N, Kandhasamy S, Kang GW, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kashyap R, Kasprzack M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kawaguchi K, Kawai N, Kawasaki T, Keerthana NV, Kéfélian F, Keitel D, Kennedy R, Key JS, Khalili FY, Khan H, Khan I, Khan S, Khan Z, Khazanov EA, Khursheed M, Kijbunchoo N, Kim C, Kim C, Kim JC, Kim J, Kim K, Kim W, Kim WS, Kim YM, Kimball C, Kimura N, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kita N, Kitazawa H, Kleybolte L, Klika JH, Klimenko S, Knowles TD, Knyazev E, Koch P, Koehlenbeck SM, Koekoek G, Kojima Y, Kokeyama K, Koley S, Komori K, Kondrashov V, Kong AKH, Kontos A, Koper N, Korobko M, Korth WZ, Kotake K, Kowalska I, Kozak DB, Kozakai C, Kozu R, Kringel V, Krishnendu N, Królak A, Kuehn G, Kumar A, Kumar P, Kumar R, Kumar R, Kumar S, Kume J, Kuo CM, Kuo HS, Kuo L, Kuroyanagi S, Kusayanagi K, Kutynia A, Kwak K, Kwang S, Lackey BD, Lai KH, Lam TL, Landry M, Lane BB, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche YK, Lee CH, Lee HK, Lee HM, Lee HW, Lee J, Lee K, Lee RK, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li J, Li KJL, Li TGF, Li X, Lin CY, Lin F, Lin FL, Lin LCC, Linde F, Linker SD, Littenberg TB, Liu GC, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lower ME, Lück H, Lumaca D, Lundgren AP, Luo LW, Lynch R, Ma Y, Macas R, Macfoy S, MacInnis M, Macleod DM, Macquet A, Magaña-Sandoval F, Zertuche LM, Magee RM, Majorana E, Maksimovic I, Malik A, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marchio M, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin IW, Martin RM, Martynov DV, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Mehta AK, Meidam J, Melatos A, Mendell G, Mercer RA, Mereni L, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Michimura Y, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Millhouse M, Mills JC, Milovich-Goff MC, Minazzoli O, Minenkov Y, Mio N, Mishkin A, Mishra C, Mistry T, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Miyakawa O, Miyamoto A, Miyazaki Y, Miyo K, Miyoki S, Mo G, Moffa D, Mogushi K, Mohapatra SRP, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Moriwaki Y, Mours B, Mow-Lowry CM, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagano K, Nagano S, Nagar A, Nakamura K, Nakano H, Nakano M, Nakashima R, Nardecchia I, Narikawa T, Naticchioni L, Nayak RK, Negishi R, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Ng KY, Ng S, Nguyen P, Ni WT, Nichols D, Nishizawa A, Nissanke S, Nocera F, North C, Nuttall LK, Obergaulinger M, Oberling J, O’Brien BD, Obuchi Y, O’Dea GD, Ogaki W, Ogin GH, Oh JJ, Oh SH, Ohashi M, Ohishi N, Ohkawa M, Ohme F, Ohta H, Okada MA, Okutomi K, Oliver M, Oohara K, Ooi CP, Oppermann P, Oram RJ, O’Reilly B, Ormiston RG, Ortega LF, O’Shaughnessy R, Oshino S, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan HW, Pan KC, Pang B, Pang HF, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Park J, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedersen C, Pedraza M, Pedurand R, Pele A, Arellano FEP, Penn S, Perez CJ, Perreca A, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piergiovanni F, Pillant G, Pinard L, Pinto I, Pirello M, Pitkin M, Poggiani R, Pong DYT, Ponrathnam S, Popolizio P, Porter EK, Powell J, Prajapati AK, Prasad J, Prasai K, Prasanna R, Pratten G, Prestegard T, Privitera S, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quinonez PJ, Quintero EA, Quitzow-James R, Raab FJ, Radkins H, Radulescu N, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rao K, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Ricci F, Richardson CJ, Richardson JW, Ricker PM, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romanelli M, Romano R, Romel CL, Romie JH, Rose K, Rosińska D, Rosofsky SG, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sago N, Saito S, Saito Y, Sakai K, Sakai Y, Sakamoto H, Sakellariadou M, Sakuno Y, Salconi L, Saleem M, Samajdar A, Sammut L, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Santiago KA, Sarin N, Sassolas B, Sathyaprakash BS, Sato S, Sato T, Sauter O, Savage RL, Sawada T, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sekiguchi T, Sekiguchi Y, Sellers D, Sengupta AS, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer T, Shahriar MS, Shaner MB, Shao L, Sharma P, Shawhan P, Shen H, Shibagaki S, Shimizu R, Shimoda T, Shimode K, Shink R, Shinkai H, Shishido T, Shoda A, Shoemaker DH, Shoemaker DM, ShyamSundar S, Siellez K, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh N, Singhal A, Sintes AM, Sitmukhambetov S, Skliris V, Slagmolen BJJ, Slaven-Blair TJ, Smith JR, Smith RJE, Somala S, Somiya K, Son EJ, Sorazu B, Sorrentino F, Sotani H, Souradeep T, Sowell E, Spencer AP, Srivastava AK, Srivastava V, Staats K, Stachie C, Standke M, Steer DA, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson SP, Stocks D, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Sudhir V, Sugimoto R, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Suzuki T, Suzuki T, Swinkels BL, Szczepańczyk MJ, Tacca M, Tagoshi H, Tait SC, Takahashi H, Takahashi R, Takamori A, Takano S, Takeda H, Takeda M, Talbot C, Talukder D, Tanaka H, Tanaka K, Tanaka K, Tanaka T, Tanaka T, Tanioka S, Tanner DB, Tápai M, Martin ENTS, Taracchini A, Tasson JD, Taylor R, Telada S, Thies F, Thomas M, Thomas P, Thondapu SR, Thorne KA, Thrane E, Tiwari S, Tiwari S, Tiwari V, Toland K, Tomaru T, Tomigami Y, Tomura T, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Tringali MC, Trovato A, Trozzo L, Trudeau R, Tsang KW, Tsang TTL, Tse M, Tso R, Tsubono K, Tsuchida S, Tsukada L, Tsuna D, Tsuzuki T, Tuyenbayev D, Uchikata N, Uchiyama T, Ueda A, Uehara T, Ueno K, Ueshima G, Ugolini D, Unnikrishnan CS, Uraguchi F, Urban AL, Ushiba T, Usman SA, Vahlbruch H, Vajente G, Valdes G, Bakel NV, Beuzekom MV, Brand JFJVD, Broeck CVD, Vander-Hyde DC, Schaaf LVD, Heijningen JVV, Putten MHPMV, Veggel AAV, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vine DJ, Vinet JY, Vitale S, Vivanco FH, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang J, Wang JZ, Wang WH, Wang YF, Ward RL, Warden ZA, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Wessel EK, Weßels P, Westhouse JW, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken DM, Williams D, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Worden J, Wright JL, Wu CM, Wu DS, Wu HC, Wu SR, Wysocki DM, Xiao L, Xu WR, Yamada T, Yamamoto H, Yamamoto K, Yamamoto K, Yamamoto T, Yancey CC, Yang L, Yap MJ, Yazback M, Yeeles DW, Yokogawa K, Yokoyama J, Yokozawa T, Yoshioka T, Yu H, Yu H, Yuen SHR, Yuzurihara H, Yvert M, Zadrożny AK, Zanolin M, Zeidler S, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang T, Zhao C, Zhao Y, Zhou M, Zhou Z, Zhu XJ, Zhu ZH, Zimmerman AB, Zucker ME, Zweizig J. Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA. LIVING REVIEWS IN RELATIVITY 2020; 23:3. [PMID: 33015351 PMCID: PMC7520625 DOI: 10.1007/s41114-020-00026-9] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 05/27/2020] [Indexed: 05/05/2023]
Abstract
We present our current best estimate of the plausible observing scenarios for the Advanced LIGO, Advanced Virgo and KAGRA gravitational-wave detectors over the next several years, with the intention of providing information to facilitate planning for multi-messenger astronomy with gravitational waves. We estimate the sensitivity of the network to transient gravitational-wave signals for the third (O3), fourth (O4) and fifth observing (O5) runs, including the planned upgrades of the Advanced LIGO and Advanced Virgo detectors. We study the capability of the network to determine the sky location of the source for gravitational-wave signals from the inspiral of binary systems of compact objects, that is binary neutron star, neutron star-black hole, and binary black hole systems. The ability to localize the sources is given as a sky-area probability, luminosity distance, and comoving volume. The median sky localization area (90% credible region) is expected to be a few hundreds of square degrees for all types of binary systems during O3 with the Advanced LIGO and Virgo (HLV) network. The median sky localization area will improve to a few tens of square degrees during O4 with the Advanced LIGO, Virgo, and KAGRA (HLVK) network. During O3, the median localization volume (90% credible region) is expected to be on the order of 10 5 , 10 6 , 10 7 Mpc 3 for binary neutron star, neutron star-black hole, and binary black hole systems, respectively. The localization volume in O4 is expected to be about a factor two smaller than in O3. We predict a detection count of 1 - 1 + 12 ( 10 - 10 + 52 ) for binary neutron star mergers, of 0 - 0 + 19 ( 1 - 1 + 91 ) for neutron star-black hole mergers, and 17 - 11 + 22 ( 79 - 44 + 89 ) for binary black hole mergers in a one-calendar-year observing run of the HLV network during O3 (HLVK network during O4). We evaluate sensitivity and localization expectations for unmodeled signal searches, including the search for intermediate mass black hole binary mergers.
Collapse
|
118
|
Feng YG, Zhao JF, Xiao L, Rao WY, Ran C, Xiao YH. MicroRNA-19a-3p suppresses invasion and metastasis of prostate cancer via inhibiting SOX4. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2019; 22:6245-6251. [PMID: 30338791 DOI: 10.26355/eurrev_201810_16031] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To explore the role of microRNA-19a-3p in regulating invasion, metastasis and EMT (epithelial mesenchymal transition) of prostate cancer (PCa) cells, as well as its underlying mechanism. MATERIALS AND METHODS MicroRNA-19a-3p mimic and negative control plasmid were first constructed. After transfection of microRNA-19a-3p mimic or negative control in DU145 cells, expression levels of microRNA-19a-3p and SOX4 were detected by quantitative Real-time-polymerase chain reaction (qRT-PCR) and Western blot. The regulatory effects of microRNA-19a-3p on migration and invasion of DU145 cells were detected by wound healing assay and transwell assay, respectively. Protein levels of matrix metalloproteinase-2 (MMP2), matrix metalloproteinase-9 (MMP9), N-cadherin, Vimentin, alpha-smooth muscle actin (α-SMA) and E-cadherin in DU145 cells transfected with microRNA-19a-3p mimic or negative control were detected by Western blot. RESULTS Overexpression of microRNA-19a-3p inhibited protein level of SOX4 in DU145 cells. The migration and invasion of DU145 cells were inhibited after transfection of microRNA-19a-3p mimic. Protein levels of MMP2, MMP9, N-cadherin, Vimentin and α-SMA were downregulated, whereas E-cadherin was upregulated after microRNA-19a-3p overexpression. CONCLUSIONS MicroRNA-19a-3p inhibits migration, invasion and EMT of PCa cells via inhibiting SOX4.
Collapse
|
119
|
Tse M, Yu H, Kijbunchoo N, Fernandez-Galiana A, Dupej P, Barsotti L, Blair CD, Brown DD, Dwyer SE, Effler A, Evans M, Fritschel P, Frolov VV, Green AC, Mansell GL, Matichard F, Mavalvala N, McClelland DE, McCuller L, McRae T, Miller J, Mullavey A, Oelker E, Phinney IY, Sigg D, Slagmolen BJJ, Vo T, Ward RL, Whittle C, Abbott R, Adams C, Adhikari RX, Ananyeva A, Appert S, Arai K, Areeda JS, Asali Y, Aston SM, Austin C, Baer AM, Ball M, Ballmer SW, Banagiri S, Barker D, Bartlett J, Berger BK, Betzwieser J, Bhattacharjee D, Billingsley G, Biscans S, Blair RM, Bode N, Booker P, Bork R, Bramley A, Brooks AF, Buikema A, Cahillane C, Cannon KC, Chen X, Ciobanu AA, Clara F, Cooper SJ, Corley KR, Countryman ST, Covas PB, Coyne DC, Datrier LEH, Davis D, Di Fronzo C, Driggers JC, Etzel T, Evans TM, Feicht J, Fulda P, Fyffe M, Giaime JA, Giardina KD, Godwin P, Goetz E, Gras S, Gray C, Gray R, Gupta A, Gustafson EK, Gustafson R, Hanks J, Hanson J, Hardwick T, Hasskew RK, Heintze MC, Helmling-Cornell AF, Holland NA, Jones JD, Kandhasamy S, Karki S, Kasprzack M, Kawabe K, King PJ, Kissel JS, Kumar R, Landry M, Lane BB, Lantz B, Laxen M, Lecoeuche YK, Leviton J, Liu J, Lormand M, Lundgren AP, Macas R, MacInnis M, Macleod DM, Márka S, Márka Z, Martynov DV, Mason K, Massinger TJ, McCarthy R, McCormick S, McIver J, Mendell G, Merfeld K, Merilh EL, Meylahn F, Mistry T, Mittleman R, Moreno G, Mow-Lowry CM, Mozzon S, Nelson TJN, Nguyen P, Nuttall LK, Oberling J, Oram RJ, O'Reilly B, Osthelder C, Ottaway DJ, Overmier H, Palamos JR, Parker W, Payne E, Pele A, Perez CJ, Pirello M, Radkins H, Ramirez KE, Richardson JW, Riles K, Robertson NA, Rollins JG, Romel CL, Romie JH, Ross MP, Ryan K, Sadecki T, Sanchez EJ, Sanchez LE, Saravanan TR, Savage RL, Schaetzl D, Schnabel R, Schofield RMS, Schwartz E, Sellers D, Shaffer TJ, Smith JR, Soni S, Sorazu B, Spencer AP, Strain KA, Sun L, Szczepańczyk MJ, Thomas M, Thomas P, Thorne KA, Toland K, Torrie CI, Traylor G, Urban AL, Vajente G, Valdes G, Vander-Hyde DC, Veitch PJ, Venkateswara K, Venugopalan G, Viets AD, Vorvick C, Wade M, Warner J, Weaver B, Weiss R, Willke B, Wipf CC, Xiao L, Yamamoto H, Yap MJ, Yu H, Zhang L, Zucker ME, Zweizig J. Quantum-Enhanced Advanced LIGO Detectors in the Era of Gravitational-Wave Astronomy. PHYSICAL REVIEW LETTERS 2019; 123:231107. [PMID: 31868462 DOI: 10.1103/physrevlett.123.231107] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Indexed: 06/10/2023]
Abstract
The Laser Interferometer Gravitational Wave Observatory (LIGO) has been directly detecting gravitational waves from compact binary mergers since 2015. We report on the first use of squeezed vacuum states in the direct measurement of gravitational waves with the Advanced LIGO H1 and L1 detectors. This achievement is the culmination of decades of research to implement squeezed states in gravitational-wave detectors. During the ongoing O3 observation run, squeezed states are improving the sensitivity of the LIGO interferometers to signals above 50 Hz by up to 3 dB, thereby increasing the expected detection rate by 40% (H1) and 50% (L1).
Collapse
|
120
|
Zhao P, Xiao L, Peng J, Qian YQ, Huang CC. Exosomes derived from bone marrow mesenchymal stem cells improve osteoporosis through promoting osteoblast proliferation via MAPK pathway. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2019; 22:3962-3970. [PMID: 29949171 DOI: 10.26355/eurrev_201806_15280] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Osteoporosis is the most common bone metabolic disease. Exosome exerts a crucial role in the development of multiple diseases. The aim of the study was to investigate the role of exosome derived from bone marrow mesenchymal stem cells (MSCs) in osteoporosis and its underlying mechanism. MATERIALS AND METHODS MSCs were first isolated from rat bone marrow. After the surface antigen of MSCs was identified by flow cytometry, MSCs-derived exosomes (MSC-Exo) was extracted. The osteogenic and lipid differentiation abilities of BMSCs were determined by alizarin red staining and oil red staining, respectively. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of genes. Cell counting kit-8 (CCK-8) assay was used to detect the viability of hFOB 1.19 cells. Western blot was used to measure expressions of the specific surface markers in exosomes and the MAPK pathway-related proteins in hFOB 1.19 cells. Moreover, cell cycle of hFOB 1.19 was detected by flow cytometry. RESULTS We observed a positive identification of surface antigens in MSCs, which presented good multidirectional differentiation ability. The isolated MSC-Exo exhibited typical morphology and particle size of exosomes, and the detection of specific surface labeled protein was positive under an electron microscope. After co-culture of MSC-Exo and osteoblast cell line hFOB 1.19, we found that MSC-Exo could promote the proliferation of hFOB 1.19 cells. Moreover, mRNA and protein expressions of GLUT3 in cells were increased, and the cell cycle was also promoted. The expressions of related proteins in the MAPK signaling pathway were found to be promoted. Rescue experiments demonstrated that MSC-Exo could promote the growth and cell cycle of hFOB 1.19, which were reversed by p-JNK knockdown. CONCLUSIONS MSC-derived exosomes improve osteoporosis by promoting the proliferation of osteoblasts via MAPK pathway.
Collapse
|
121
|
Yang XZ, Gen AW, Xian JC, Xiao L. Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2019; 22:479-485. [PMID: 29424906 DOI: 10.26355/eurrev_201801_14198] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Hepatic fibrosis is a repair response to chronic liver injury. This study evaluated the diagnostic value of various noninvasive indicators for hepatic fibrosis in patients with chronic liver disease. PATIENTS AND METHODS 95 patients with liver biopsy were enrolled in this study. Routine clinical and laboratory examinations were collected, including age, sex, blood routine, biochemistry, serum fibrosis, and FibroTouch. APRI and FIB4 scores were calculated. The patients were grouped according to liver pathological staging to analyze the correlation between the fibrosis with serum fibrosis, APRI, FIB4 score, and FibroTouch. The receiver operator characteristics of S2, S3, and S4 were analyzed to calculate the area under the curve (AUC). RESULTS No statistical difference was found on age, ALT, AST, GGT, BMI, TG, CHOL, and Glu (p > 0.05). Liver stiffness measurement (LSM), APRI, FIB4, PCIII, CIV, LN, and HA exhibited statistical significance (p < 0.05). Further correlation analysis showed that PCIII, IV-C, LN, APRI, LSM, and FIB4 were positively correlated with the stage of hepatic fibrosis (p < 0.05). ROC curve analysis demonstrated that LSM and FIB4 revealed good predictions of various stages of fibrosis in chronic liver disease with AUC greater than 0.7. The AUC of LSM in the diagnosis of liver cirrhosis (S4) reached 0.908. Its accuracy was influenced by liver inflammation. CONCLUSIONS The LSM value in FibroTouch showed high coincidence rate with hepatic fibrosis staging. It is a valuable noninvasive method for assessing the progression of hepatic fibrosis in chronic liver disease.
Collapse
|
122
|
Wiele A, Ross J, Chahoud J, Lim Z, Xiao L, Campbell M, Shah A, Zurita Saavedra A, Jonasch E, Tannir N. Lenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.060] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
123
|
Li DY, Yu JC, Xiao L, Miao W, Ji K, Wang SC, Geng YX. Autophagy attenuates the oxidative stress-induced apoptosis of Mc3T3-E1 osteoblasts. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2019; 21:5548-5556. [PMID: 29271985 DOI: 10.26355/eurrev_201712_13991] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The oxidative stress-induced osteoblast apoptosis plays an important role in the pathological process of osteoporosis, but the roles of autophagy in oxidative stress and apoptosis of osteoblasts remain unclear. This study aimed to observe the role of autophagy in oxidative stress injury of osteoblasts and the relationship between autophagy and apoptosis. MATERIALS AND METHODS Mc3T3-E1 cells were stimulated with different concentrations (0.1, 0.5, and 1 mM) of hydrogen peroxide. The cell viability was detected via cell counting kit 8 (CCK8) at different time points (0, 2, 6, 8, and 12 h), the apoptosis was detected via Western blotting and flow cytometry, and the autophagy was detected via macrophage-derived chemokine (MDC) and transmission electron microscope. The changes in expression of autophagy-associated protein, Beclin1, and LC3II/I ratio, were detected via Western blotting. Moreover, the intracellular reactive oxygen species (ROS) level and extracellular superoxide dismutase (SOD) level were observed using the autophagy regulators, rapamycin (Rap) and 3-methyladenine (3-MA), so as to clarify the interaction between autophagy and cellular oxidation. RESULTS Hydrogen peroxide-induced apoptosis and autophagy of osteoblasts were in dose- and time-dependent manners; the hydrogen peroxide inhibitors could inhibit the autophagy level, and autophagy inhibitor (3-MA) could significantly enhance the hydrogen peroxide-induced ROS level and apoptosis rate in cells. Besides, Western blotting confirmed that the cleaved caspase-3 and cleaved poly adenosine diphosphate ribose polymerase (PARP) proteins were increased. The autophagy inducer (Rap) partially inhibited the hydrogen peroxide-induced oxidative stress and apoptosis. CONCLUSIONS Autophagy inhibits the oxidative stress-mediated apoptosis of osteoblasts, which is a potential target for the osteoporosis treatment.
Collapse
|
124
|
Xiao L, Gong C, Ding Y, Ding G, Xu X, Deng C, Ze X, Malard P, Ben X. Probiotics maintain intestinal secretory immunoglobulin A levels in healthy formula-fed infants: a randomised, double-blind, placebo-controlled study. Benef Microbes 2019; 10:729-739. [PMID: 31965842 DOI: 10.3920/bm2019.0025] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Formula-fed infants are more susceptible to infectious diseases because they lack the maternal immune factors transferred from breast milk, while their own immune system is still immature. As timely probiotic administration was suggested to promote immune system development in formula-fed infants, this study aimed at assessing the safety and the effects of a probiotic supplement (Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052) on mucosal immune competence and digestive function in formula-fed infants. Healthy infants (3.5-6 months old) were randomised to receive either probiotic- (n=66) or placebo-supplemented (n=66) formula once a day for four weeks. In the probiotics group, faecal secretory immunoglobulin A (SIgA) levels remained similar between visit 2 (baseline; V2) and visit 3 (end-of-treatment; V3), but decreased in the placebo group. Changes in SIgA levels following treatment (log10ΔV3-V2 [95%CI]) between the probiotic and placebo groups were statistically significant (23 ng/dl [-57;102] and -137 ng/dl [-212;-62], respectively (P=0.0044; ANCOVA)). While log10ΔV3-V2 [95%CI] for salivary SIgA levels increased in both groups, this trend was more pronounced in the probiotics than in the placebo group with an increase of 123 ng/dl [9;236] and 37 ng/dL [-72;147], respectively (P=0.2829; ANCOVA). The weekly average number of stools/day was significantly higher in the probiotics group compared to placebo during the last week of treatment for the per protocol population. There was no difference in microbiota composition or anthropometric parameters between groups. No serious adverse event was reported, and all adverse events were mild and unrelated to the product or study. Our results show that formula-fed infants receiving probiotics maintained higher faecal SIgA levels at the end of the four-week treatment period, suggesting a positive effect of probiotics on SIgA production. This study demonstrates the safety of this probiotic formulation in infants. Formula-fed infants may benefit from probiotics supplementation to sustain the development of mucosal immunity.
Collapse
|
125
|
Yang H, Ye L, Su L, Liu Y, Xiao L, Hu Y, Wei DB, Yuan D, Zhou GS, Liu HL, Yu J, Liang S. [An analysis on incidence of HIV-1 epidemics among men who have sex with men in Sichuan Province during 2011-2015]. ZHONGHUA YU FANG YI XUE ZA ZHI [CHINESE JOURNAL OF PREVENTIVE MEDICINE] 2019; 53:327-329. [PMID: 30841677 DOI: 10.3760/cma.j.issn.0253-9624.2019.03.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The assay was used in HIV/AIDS surveillance sentinel sites to identify recent HIV-1 infection, to estimate HIV-1 incidence and understand the epidemic trends among men who have sex with men during 2011-2015. During 2011-2015, the HIV-1 incidence of men who have sex with men was 5.16%(95%CI: 4.65%-5.66%) in Sichuan Province. According to<Pilot study on classification criteria of AIDS epidemic in China>, a total of 9 cities had been divided into two type of regions: the first type(the proportion of live HIV/AIDS accounts for more than 0.1% of the permanent population, and the number of live HIV/AIDS has reached 500 cases and above) and the second type(the proportion of live HIV/AIDS accounts for 0.03% to 0.100% of the permanent population, and the number of live HIV/AIDS has reached 100-500 cases). During 2011-2015, the HIV-1 incidence of the second type was 4.24% (95%CI: 3.72%-4.76%). The HIV-1 incidence of men who have sex with men was at a high level. The spread of HIV-1 to the second region was possible.
Collapse
|